Philadelphia, Pennsylvania--(Newsfile Corp. - February 28, 2024) - Grabar Law Office is investigating claims on behalf of Fate Therapeutics, Inc. (NASDAQ: FATE) shareholders. The investigation concerns whether certain officers of Fate Therapeutics have breached their fiduciary duties owed to the company.

An underlying securities fraud class action complaint alleges that Fate Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the class action complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate Therapeutics had represented to investors; (ii) accordingly, certain of the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate Therapeutics had overstated the impact of the Janssen Collaboration Agreement's on Fate Therapeutics' long-term clinical and commercial profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Current Fate Therapeutics shareholders who have held Fate Therapeutics stock since on or before April 2, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, you are encouraged visit https://grabarlaw.com/the-latest/fate-therapeutics-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call Joshua Grabar at 267-507-6085.

Attorney Advertising Disclaimer

Contact:Joshua H. Grabar, Esq.Grabar Law OfficeOne Liberty Place1650 Market Street, Suite 3600Philadelphia, PA 19103Tel: 267-507-6085Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/199652

COMTEX_448482244/2523/2024-02-28T09:17:12